Advisory Services Network LLC Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Advisory Services Network LLC decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,952 shares of the medical research company’s stock after selling 89 shares during the period. Advisory Services Network LLC’s holdings in Charles River Laboratories International were worth $698,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CRL. VisionPoint Advisory Group LLC grew its position in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Charles River Laboratories International in the third quarter valued at $37,000. Operose Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the third quarter valued at $42,000. Provence Wealth Management Group purchased a new stake in shares of Charles River Laboratories International in the third quarter valued at $57,000. Finally, GAMMA Investing LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $62,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.6 %

Shares of CRL opened at $208.54 on Friday. The stock’s 50-day moving average is $236.53 and its two-hundred day moving average is $230.37. The stock has a market cap of $10.74 billion, a PE ratio of 24.53, a P/E/G ratio of 2.00 and a beta of 1.44. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37.

Charles River Laboratories International (NYSE:CRLGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares in the company, valued at $5,282,953.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Citigroup lifted their price objective on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. UBS Group lifted their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Argus lifted their target price on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a report on Monday, March 18th. Finally, TD Cowen reduced their target price on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a report on Monday, May 13th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus target price of $255.27.

Get Our Latest Research Report on CRL

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLFree Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.